Reunion Neuroscience Inc.
REUN · NASDAQ
3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | -0.05 | -0.01 | 0.00 |
| FCF Yield | -259.33% | -49.49% | -10.14% | -13.72% |
| EV / EBITDA | 0.76 | -1.06 | -7.27 | -1.86 |
| Quality | ||||
| ROIC | -82.61% | -54.79% | -15.68% | -27.36% |
| Gross Margin | 0.00% | -88.27% | -60.72% | -840.30% |
| Cash Conversion Ratio | 0.58 | 0.81 | 0.71 | 0.73 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | 1,593.88% | 986,691.30% | 99,900.00% |
| Free Cash Flow Growth | 41.19% | -152.91% | -559.41% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 1.39 | 0.59 | 1.45 | 1.16 |
| Interest Coverage | -1.15 | -47.98 | -62.57 | -145.03 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 11.78 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 123.26 | 309.11 | -47,211.97 |